Error loading player: No playable sources found

AM24-TU-11-O

AM24-TU-11-O: Managing Risk, Maximizing Safety: The Essentials of Proactive Risk Assessment (Enduring)

Date
October 23, 2024
Credits
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP) | 1 Physician (PHY)
$30
Standard Price
Members save $5
This product is also available as part of the following products:
Thumbnail for 2024 AABB Annual Meeting On-Demand: BIOTHERAPIES SESSIONS
Interested in all sessions Cellular Therapy/Biotherapies? Then this is the package for you. We have also thrown in a couple of additional sessions you might also find interesting…
Thumbnail for 2024 AABB Annual Meeting On-Demand: CABP CE Eligible Sessions
Interested in sessions eligible to maintain your AABB Certified Advanced Biotherapies Professional (CABP) certification? This package provides:
Thumbnail for 2024 Annual Meeting On-Demand: FULL ACCESS
By far the best value to watch all the on-demand educational sessions from the 2024 AABB Annual Meeting and earn continuing education credit…

CABP CE Eligible

This session equips blood bank, transfusion medicine, and biotherapies professionals with practical tools for robust risk assessment. Risk identification methods and customizing risk registers for specific practice areas will be covered. Key steps in the risk assessment process like evaluation, prioritization and monitoring will be explored. Techniques for proactively assessing vulnerabilities across the full spectrum of operations, from donor screening and component preparation to blood administration will be discussed. Best practices for risk assessment, including evaluating risk levels and predictability, will be presented. Real case examples demonstrate how targeted risk mitigation enhances patient outcomes and ensures the safety of blood and biotherapies. Attendees will gain skills applicable to establishing customized risk management programs tailored to their unique needs.

Learning Objectives

  • Describe the key steps in the risk assessment process for Blood Bank, Transfusion Services, and Biotherapies
  • Apply techniques for identifying risks tailored to their specific practice areas and workflows
  • Analyze potential vulnerabilities and prioritize risks according to impact and likelihood within their facilities

Moderator & Speaker

Speaker Image for Faisal Alsaqri
Faisal Alsaqri, MSc, CLBSSB
Laboratry Operations and quality Improvment analyst

Speaker

Speaker Image for Hillary Brown
Hillary Brown, BS, MLT
Massachusetts General Hospital Cellular Therapy Lab (CTTL)

Related Products

Thumbnail for AM24-MN-26-O: Overview of Cell-Based Biologics Manufacturing as a Contracted Service (Enduring)
AM24-MN-26-O: Overview of Cell-Based Biologics Manufacturing as a Contracted Service (Enduring)
Decentralized manufacturing has become a prominent focus in the Advanced Therapies space as the number of therapies in development increases and patient volumes surge with earlier line treatment objectives…
Thumbnail for AM24-TU-06-O: Oral Abstracts - Biotherapy Spotlight (Enduring)
AM24-TU-06-O: Oral Abstracts - Biotherapy Spotlight (Enduring)
The Biotherapies Spotlight Session will cover several diverse topics. The use of controlled incremental filtration microfluidics rather than monoclonal antibody selection systems to isolate B-cells from whole blood will be discussed…
Thumbnail for AM24-MN-32-O: Lyophilized, Stem-cell Derived, and Synthetic Platelet Products are Closer Than You May Think (Enduring)
AM24-MN-32-O: Lyophilized, Stem-cell Derived, and Synthetic Platelet Products are Closer Than You May Think (Enduring)
This session will highlight advances in three areas of platelet research; stabilization methods through lyophilization, iPSC ex-vivo production, and synthetic nanoparticle technology are converging and can lead to long-lived platelet-based therapies targeted to address specific related pathologies…
Thumbnail for AM24-MN-31-O: Cell Therapy: Creative Inventory Management & Discard (Enduring)
AM24-MN-31-O: Cell Therapy: Creative Inventory Management & Discard (Enduring)
A presentation of how one facility tackled a massive inventory reduction project to discard cell therapy products that had been in LN2 storage for 10 to 25 years…